Advertising of erectile dysfunction products to consumers violates voluntary US guidelinesBMJ 2013; 346 doi: http://dx.doi.org/10.1136/bmj.f1225 (Published 22 February 2013) Cite this as: BMJ 2013;346:f1225
- Bob Roehr
The pharmaceutical drug industry has consistently failed to adhere to its own self regulation guidelines for direct to consumer advertising of erectile dysfunction (ED) drugs, according to a study1 that looked at four years of such advertising in the United States.
The pharmaceutical industry spent just $985m (£647m; €748m) advertising ED drugs to consumers in 1996. The Food and Drug Administration (FDA) loosened regulations on …
Log in using your username and password
Log in through your institution
Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
Sign up for a free trial